This database compiles published clinical outcomes from patients with advanced/metastatic NSCLC with uncommon EGFR mutations, treated with afatinib.
1247 patients are currently included in the database.
The data have been entered as reported. Central testing was only performed within the LUX-Lung trials. Different testing methods with different sensitivities may have been used. The timepoint of mutational testing is unknown for EGFR-TKI pretreated patients (at diagnosis or at progression). There is a potential bias associated with case studies/case series, as it is may be more likely that patient cases with positive outcomes are published.
Please feel free to contact us with cases of new or missing data (The data must have been published in a peer-reviewed journal).
Disclaimer
You are leaving the Uncommon EGFR Mutations website. You are being directed to a third-party website. This link is provided for your convenience. Please note that the third-party website is not under the control of the Boehringer Ingelheim Corporation and not subject to the privacy policy of this website.
Do you want to continue ?